Vaccinex Granted U.S. Patent #12070500: Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
Portfolio Pulse from Benzinga Newsdesk
Vaccinex has been granted a U.S. patent for the use of semaphorin-4D antibodies in combination with immune modulating therapy to inhibit tumor growth and metastasis. This patent could enhance Vaccinex's position in cancer treatment innovation.
August 27, 2024 | 6:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vaccinex has been granted a U.S. patent for a novel cancer treatment approach using semaphorin-4D antibodies with immune modulating therapy. This could strengthen Vaccinex's market position in oncology.
The granting of a U.S. patent for a new cancer treatment method is a significant milestone for Vaccinex. It could lead to increased interest and investment in the company, as well as potential partnerships or collaborations in the oncology field. This development is likely to positively impact Vaccinex's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100